Parallel Advisors LLC Acquires New Position in Cocrystal Pharma Inc (OTCMKTS:COCP)

Parallel Advisors LLC purchased a new position in Cocrystal Pharma Inc (OTCMKTS:COCP) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 48,499 shares of the company’s stock, valued at approximately $99,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wasatch Advisors Inc. raised its holdings in shares of Cocrystal Pharma by 5.4% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,152,731 shares of the company’s stock worth $2,709,000 after acquiring an additional 59,235 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Cocrystal Pharma by 15.3% during the 2nd quarter. BlackRock Inc. now owns 35,323 shares of the company’s stock worth $83,000 after acquiring an additional 4,685 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Cocrystal Pharma by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 360,364 shares of the company’s stock worth $847,000 after acquiring an additional 15,336 shares in the last quarter.

Shares of COCP traded down $0.13 during mid-day trading on Tuesday, hitting $0.48. 358,216 shares of the stock were exchanged, compared to its average volume of 26,480. Cocrystal Pharma Inc has a 52-week low of $0.60 and a 52-week high of $5.28. The firm has a 50-day moving average of $1.40 and a two-hundred day moving average of $2.08.

Cocrystal Pharma (OTCMKTS:COCP) last issued its quarterly earnings data on Friday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $0.59 million during the quarter.

Cocrystal Pharma Profile

Cocrystal Pharma, Inc, formerly Biozone Pharmaceuticals, Inc, is engaged in developing medicines for use in the treatment of human viral diseases. The Company develops technologies and approaches to create antiviral drug candidates. The Company is developing antiviral therapeutics that inhibit the replication function of a virus, including the ribonucleic acid (RNA)-dependent RNA polymerase enzyme, the helicase enzyme and the NS5A protein of hepatitis C virus (HCV), and the polymerase enzymes of influenza virus and norovirus.

Further Reading: What is a back-end load?

Want to see what other hedge funds are holding COCP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cocrystal Pharma Inc (OTCMKTS:COCP).

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.